



TELEPHONE: 512/474-5201
FAXIMILE: 512/436-4598

WRITER'S INTERNET ADDRESS:
RHANSON@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:
512/536-3085

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

03-114-0400
HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.

March 5, 2002

Date

Robert E. Hanson

March 5, 2002

FILE: TEXG:003USDI

Commissioner for Patents
Washington, DC 20231

RE: *SN 10/047,251 "GENETIC AND EPIGENETIC MANIPULATION OF ABC TRANSPORTERS AND ECTO-PHOSPHATASES FOR THE CONFERENCE OF DRUG RESISTANCE AND FOR THE LOSS OF DRUG RESISTANCE IN BIOLOGICAL SYSTEMS AND METHODS FOR THE DETECTION OF ECTO-PHOSPHATASE INHIBITORS" - by J. Brian Windsor et al.*

COPY OF PAPERS
ORIGINALLY FILED

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110234/REH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Robert E. Hanson
Reg. No. 42,628

REH/cas
Encl: as noted